CordenPharma and Viking Therapeutics Forge a Strategic Alliance
CordenPharma has recently entered into a significant multi-year strategic partnership with Viking Therapeutics, a clinical-stage company renowned for developing innovative therapies aimed at metabolic and endocrine disorders. This collaboration focuses on the integrated supply of Viking’s promising GLP-1 drug candidate, VK2735.
Partnership Overview
Through the synergy of this partnership, CordenPharma will leverage its large-scale peptide manufacturing capabilities to support the commercial needs associated with the VK2735 drug candidate. This drug functions as a Dual GLP-1/GIP Receptor Agonist and is expected to play a crucial role in treating metabolic conditions.
Manufacturing and Development Support
CordenPharma's expertise extends to providing essential fill-finish services for VK2735’s subcutaneous formulation. Additionally, the company will handle oral solid dosage manufacturing for the injectable and oral peptide formats, ensuring comprehensive support from the early development stages to commercial production.
Securing the Supply Chain
With a commitment to maintaining an uninterrupted supply, CordenPharma is strategically enhancing its operational model. The company’s established global network of cutting-edge facilities allows for redundancy, safeguarding against potential disruptions in the supply chain during the lifecycle of VK2735.
Leadership Insights
Dr. Michael Quirmbach, the President & CEO of the CordenPharma Group, expressed excitement over this partnership. He emphasized the importance of offering a unified service model capable of meeting the growing demand for GLP-1 therapeutics. Dr. Quirmbach stated, "We are proud to support Viking Therapeutics with a strong offering that encompasses everything from peptide drug substance to drug product. Our teams are keen to drive better patient outcomes through collaboration."
About CordenPharma
CordenPharma stands as a prominent Contract Development and Manufacturing Organization (CDMO) providing essential services to biotech and pharmaceutical innovators. The company’s scope encompasses complex modalities throughout the drug development lifecycle, supporting customers from initial clinical phases to market launch.
Focus Areas and Expertise
With a rich foundation in scientific expertise, CordenPharma specializes in areas such as peptides, oligonucleotides, and customized lipid excipients. Their comprehensive outsourcing services create a robust framework for clients aiming at efficient drug development timelines.
Global Reach and Impact
The CordenPharma Group operates across eleven facilities located in Europe and North America. In recent years, the organization has experienced considerable growth, achieving sales of €854 million and employing over 3,000 personnel. Following the acquisition by a leading private equity firm specializing in healthcare, CordenPharma is positioned to deepen its impact in the peptide manufacturing sector.
Looking Forward
As CordenPharma and Viking Therapeutics embark on this journey together, they are set to enhance therapeutic options available for conditions requiring innovative treatments. Their collaboration signifies a vital step toward bridging the gap between drug development and patient care.
Frequently Asked Questions
What is the focus of the partnership between CordenPharma and Viking Therapeutics?
The partnership primarily focuses on supplying Viking's GLP-1 drug candidate VK2735, addressing the growing commercial need for effective therapies.
What services will CordenPharma provide in this partnership?
CordenPharma will provide large-scale peptide manufacturing, fill-finish services, and oral solid dosage manufacturing for VK2735.
Who is Dr. Michael Quirmbach?
Dr. Michael Quirmbach is the President & CEO of CordenPharma and has expressed support for the partnership, highlighting its importance in healthcare.
What geographical regions does CordenPharma serve?
CordenPharma operates facilities across Europe and North America, enhancing its global reach and manufacturing capabilities.
How does this partnership benefit patients?
This partnership aims to improve patient outcomes by providing accessible, innovative therapies for metabolic disorders.
